Log In Get Started
Press Releases May 12, 2026 08:30 AM

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
LXRX

Lexicon Pharmaceuticals announced that its management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, highlighting its ongoing commitment to investor communication and showcasing its diverse drug pipeline focused on neuropathic pain, hypertrophic cardiomyopathy, obesity, and cardiometabolic disorders.

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
LXRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lexicon will present at a major investor conference held at Nasdaq headquarters, enhancing investor visibility.
  • The company is advancing multiple drug candidates in various stages targeting neuropathic pain, HCM, obesity, and metabolic disorders.
  • The event provides an opportunity to engage with investors and emphasize corporate strategy and pipeline progress.

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.

The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.

About Lexicon Pharmaceuticals   
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.  

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
[email protected]

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
[email protected]


Risks

  • Drug development inherently carries clinical trial, regulatory, and commercial risk across its pipeline targets, including neuropathic pain and cardiometabolic diseases.
  • Potential delays or setbacks in clinical trials may impact timelines and investor sentiment.
  • Competitive pressures in biopharmaceutical sectors focused on metabolic and cardiometabolic conditions could affect market positioning.

More from Press Releases

Space Exploration Technologies Corporation to Join the Nasdaq-100 Index® Beginning July 7, 2026 Jun 26, 2026 XMax Announces Up to Approximately US$25 million in AI API-Related Service Contracts and Expansion into GPU-as-a-Service Jun 26, 2026 Cartesian Growth Corporation IV Announces Closing of $275 Million Initial Public Offering Jun 26, 2026 dLocal added to membership of US small-cap Russell 2000® Index Jun 26, 2026 Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance Jun 26, 2026